Compare IDXX & AMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IDXX | AMP |
|---|---|---|
| Founded | 1983 | 1894 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.4B | 50.3B |
| IPO Year | 1996 | 2009 |
| Metric | IDXX | AMP |
|---|---|---|
| Price | $527.35 | $494.66 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 13 | 14 |
| Target Price | ★ $701.33 | $579.45 |
| AVG Volume (30 Days) | 416.7K | ★ 572.5K |
| Earning Date | 11-02-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 1.39% |
| EPS Growth | ★ 22.59 | 9.77 |
| EPS | 7.74 | ★ 21.64 |
| Revenue | $4,303,702,000.00 | ★ $18,911,000,000.00 |
| Revenue This Year | $9.73 | $5.68 |
| Revenue Next Year | $8.86 | $5.99 |
| P/E Ratio | $66.89 | ★ $22.86 |
| Revenue Growth | ★ 10.42 | 5.49 |
| 52 Week Low | $500.61 | $422.37 |
| 52 Week High | $769.98 | $572.56 |
| Indicator | IDXX | AMP |
|---|---|---|
| Relative Strength Index (RSI) | 50.09 | 32.10 |
| Support Level | $520.96 | $486.66 |
| Resistance Level | $581.28 | $515.87 |
| Average True Range (ATR) | 12.02 | 14.76 |
| MACD | 2.76 | -3.93 |
| Stochastic Oscillator | 73.69 | 21.10 |
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx derives roughly 35% of its revenue from outside the United States.
Ameriprise Financial has evolved into a diversified financial services provider that generates roughly 65% of its operating profit from advice and wealth management. With nearly $1.2 trillion in segment assets under management and advisory at year-end 2025, and with roughly 10,600 affiliated and employee advisors, Ameriprise is one of the larger US-based wealth managers. It also boasts a reasonably large asset management franchise in Columbia Threadneedle, which boasted $678 billion in assets under management at year-end 2025. The firm's third segment is its retirement and protection services business, which sells insurance products to the firm's advisory clients. After eliminations, Ameriprise had $1.69 trillion in assets under management and advisory across segments at year-end 2025.